Home › Bladder Cancer › New York › The Bronx
Bladder Cancer clinical trials in The Bronx, NY
4 studies for Bladder Cancer are looking for participants at sites in and around The Bronx (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
RecruitingPhase 2
- Montefiore Medical Center, The Bronx
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
RecruitingPhase 2
- Montefiore Medical Center, The Bronx
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- Montefiore Medical Center, The Bronx
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
RecruitingPhase 1
- North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, The Bronx
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY35 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Philadelphia, PA21 studies
- Seattle, WA21 studies
- Edison, NJ21 studies
Other studies in The Bronx
- Non-Small Cell Lung Cancer25 studies
- Breast Cancer17 studies
- Acute Myeloid Leukemia15 studies
- Lung Cancer13 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Prostate Cancer11 studies
- Heart Failure11 studies
- Head and Neck Squamous Cell Carcinoma9 studies
- Colorectal Cancer9 studies
- Metastatic Cancer9 studies
- Asthma9 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.